Pune, India, Aug. 10, 2022 (GLOBE NEWSWIRE) -- According to MarketStudyReport, that North America breast cancer therapeutics market size is expected to amass a valuation of USD 16 billion by 2028.
Furthermore, the research literature delves into the intricacies of each division in terms of consumption value, volume, past, and current growth statistics as well as revenue share to enable stakeholders have a clear understanding of market behavior so that they can expand their profitability graph in the ensuing years.
The document also includes an overview of the competitive landscape of this industry sphere that illustrates business profiles, product & service portfolios of companies, as well as the latest strategic outcomes of notable players.
Request Sample copy of this Report @ https://www.marketstudyreport.com/request-a-sample/4966049/
Growing prevalence of breast cancer, penetration of several diagnostic & screening programs, advancements in breast cancer drugs, and mounting investments in research & development are the major factors fueling the market growth.
In addition, supportive reimbursement policies will positively impact the growth trajectory of the market in the forthcoming years.
Moreover, to minimize the pervasiveness of the disease, U.S. President Joe Biden, in 2022, relaunched a program dubbed as ‘Moonshot’ to accelerate cancer research, which was first introduced in 2017. The program raised a funding of USD 1.8 million in the last 7 years and aims to reduce fatality rates of cancer by a staggering 50% over the next 25 years.
New and advanced treatment procedures like cancer vaccinations are currently being researched in congruence with chemotherapy and immunotherapy as it has been observed that cancer vaccinations have a higher success ratio in killing tumor cells. Some of these vaccinations may be customizable, while others cover a broader spectrum.
Despite the positive outlook, side effects associated with breast cancer drugs as well as their expensive nature may impede renumeration scope of the industry during the analysis timeframe.
Ask Discount of this research report at @ https://www.marketstudyreport.com/check-for-discount/4966049/
Segmental outlook: -
Based on therapy, targeted therapy segment of North America breast cancer therapeutics industry is likely to progress at a CAGR of 7.8% during the forecast period, as it is the most promising area of research that directly targets tumor cells and kills them instead of adversely degrading healthy cells, which is usually the case with conventional broad-spectrum chemotherapy and radiation procedures.
On the other hand, the chemotherapy segment held 9% industry share in 2021 and is expected to surpass a valuation of USD 1.3 billion by 2028. Chemotherapy is the standard treatment option individually or in combination with other medications for HER2+ breast cancer and triple negative breast cancer.
Regional expanse summary: -
From a geographical standpoint, U.S. breast cancer therapeutics industry amassed a valuation of USD 9.3 billion in 2021, due to the burgeoning prevalence of the disease among women in the region.
Competitive hierarchy: -
The competitive terrain of this marketplace is defined by major players such as Eisai Co. Ltd., Bristol Myers Squibb, Pfizer Inc., Sanofi S.A., Merck & Co. Inc., F. Hoffmann-La Roche AG, Amgen Inc., Novartis International AG, Eli Lilly & Company, and AstraZeneca plc.
To access a sample copy or view this report in detail along with the table of contents, please click the link below:
https://www.marketstudyreport.com/reports/north-america-breast-cancer-therapeutics-market-statistics
North America Breast Cancer Therapeutics Market by Therapy (Value, USD Million, 2017-2028)
- Immunotherapy
- Hormonal Therapy
- Targeted Therapy
- Chemotherapy
North America Breast Cancer Therapeutics Market by Region (Value, USD Million, 2017-2028)
- Canada
- United States
North America Breast Cancer Therapeutics Market, Company Profiles (Value, USD Million, 2017-2028)
- Eisai Co. Ltd.
- Sanofi S.A.
- Merck & Co. Inc.
- F. Hoffmann-La Roche AG
- Amgen Inc.
- Novartis International AG
- Bristol Myers Squibb
- Pfizer Inc.
- Eli Lilly & Company
- AstraZeneca plc
Table of Content:
Chapter 1 Methodology
1.1 Methodology
1.2 Market definition
1.3 Forecast parameters
1.4 Data sources
1.4.1 Secondary
1.4.1.1 Paid sources
1.4.1.2 Unpaid sources
1.4.2 Primary
Chapter 2 Executive Summary
2.1 North America breast cancer therapeutics industry 3600 synopsis, 2017 - 2028
2.1.1 Country trends
2.1.2 Therapy trends
Chapter 3 North America Breast Cancer Therapeutics Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.4 Analysis of COVID-19 impact on the industry
3.5 Porter's analysis
3.6 Competitive landscape, 2021
3.7 PEST analysis
Chapter 4 North America Breast Cancer Therapeutics Market, By Therapy
4.1 Market trends
4.2 Targeted therapy
4.2.1 Market estimate and forecast, by country, 2017 - 2028 (USD Million)
4.3 Hormonal therapy
4.3.1 Market estimate and forecast, by country, 2017 - 2028 (USD Million)
4.4 Chemotherapy
4.4.1 Market estimate and forecast, by country, 2017 - 2028 (USD Million)
4.5 Immunotherapy therapy
4.5.1 Market estimate and forecast, by country, 2017 - 2028 (USD Million)
Chapter 5 North America Breast Cancer Therapeutics Market, By Country
5.1 Market trends
5.2 U.S.
5.2.1 Market estimate and forecast, by therapy, 2017 - 2028 (USD Million)
5.3 Canada
5.3.1 Market estimate and forecast, by therapy, 2017 - 2028 (USD Million)
Chapter 6 Company Profiles
Related Report:
Asia Pacific Breast Cancer Therapeutics Market Forecast 2028 By Therapy, Research Report, Country Outlook, COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Driven by various public & private investments in research & treatment, Asia Pacific breast cancer therapeutics market forecast is optimistic. Breast cancer has been a serious health concern throughout parts of Asia Pacific since past few decades. Despite significant success in lowering breast cancer mortality in many high-income nations over the years, little improvement has been accomplished in low- and middle-income countries. Addressing this issue, last year, the WHO launched the Global Breast Cancer Initiative, a joint endeavor with the goal of lowering global breast cancer mortality rates by 2.5% each year through 2040, avoiding an estimated 2.5 million deaths. With more such global initiatives awaiting the industry, it is estimated that Asia Pacific breast cancer therapeutics market size will be valued at $7.5 billion by 2028.
About US:
Market Study Report is a hub for market intelligence products and services.
We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.
Our customers partner with Market Study Report, to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.
If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, is the platform that can help you in achieving any of these objectives.
